Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May;57(5):331-338.
doi: 10.1136/jmedgenet-2019-106283. Epub 2019 Nov 29.

Genetic Variability and Potential Effects on Clinical Trial Outcomes: Perspectives in Parkinson's Disease

Collaborators, Affiliations

Genetic Variability and Potential Effects on Clinical Trial Outcomes: Perspectives in Parkinson's Disease

Hampton Leonard et al. J Med Genet. .


Background: Classical randomisation of clinical trial patients creates a source of genetic variance that may be contributing to the high failure rate seen in neurodegenerative disease trials. Our objective was to quantify genetic difference between randomised trial arms and determine how imbalance can affect trial outcomes.

Methods: 5851 patients with Parkinson's disease of European ancestry data and two simulated virtual cohorts based on public data were used. Data were resampled at different sizes for 1000 iterations and randomly assigned to the two arms of a simulated trial. False-negative and false-positive rates were estimated using simulated clinical trials, and per cent difference in genetic risk score (GRS) and allele frequency was calculated to quantify variance between arms.

Results: 5851 patients with Parkinson's disease (mean (SD) age, 61.02 (12.61) years; 2095 women (35.81%)) as well as simulated patients from virtually created cohorts were used in the study. Approximately 90% of the iterations had at least one statistically significant difference in individual risk SNPs between each trial arm. Approximately 5%-6% of iterations had a statistically significant difference between trial arms in mean GRS. For significant iterations, the average per cent difference for mean GRS between trial arms was 130.87%, 95% CI 120.89 to 140.85 (n=200). Glucocerebrocidase (GBA) gene-only simulations see an average 18.86%, 95% CI 18.01 to 19.71 difference in GRS scores between trial arms (n=50). When adding a drug effect of -0.5 points in MDS-UPDRS per year at n=50, 33.9% of trials resulted in false negatives.

Conclusions: Our data support the hypothesis that within genetically unmatched clinical trials, genetic heterogeneity could confound true therapeutic effects as expected. Clinical trials should undergo pretrial genetic adjustment or, at the minimum, post-trial adjustment and analysis for failed trials.

Keywords: clinical genetics; genetics; parkinson-s disease.

Conflict of interest statement

Competing interests: ZG-O reports personal fees from Sanofi/Genzyme, Lysosomal Therapeutics, Idorsia, Denali, Prevail Therapeutics, Ventus, Deerfield and Allergan. ZG-O is also supported by the Fonds de recherche du Québec-Santé (FRQS) Chercheurs-boursiers award given in collaboration with Parkinson Quebec, and is a Parkinson Canada New Investigator awardee. AGD-W reports personal fees from Merck and Co and other from Biogen. DJS reports funding from Merck and Co.

Similar articles

See all similar articles

Cited by 2 articles

  • Genetics of Parkinson's disease: An introspection of its journey towards precision medicine.
    Bandres-Ciga S, Diez-Fairen M, Kim JJ, Singleton AB. Bandres-Ciga S, et al. Neurobiol Dis. 2020 Apr;137:104782. doi: 10.1016/j.nbd.2020.104782. Epub 2020 Jan 25. Neurobiol Dis. 2020. PMID: 31991247 Review.
  • Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia.
    Blauwendraat C, Reed X, Krohn L, Heilbron K, Bandres-Ciga S, Tan M, Gibbs JR, Hernandez DG, Kumaran R, Langston R, Bonet-Ponce L, Alcalay RN, Hassin-Baer S, Greenbaum L, Iwaki H, Leonard HL, Grenn FP, Ruskey JA, Sabir M, Ahmed S, Makarious MB, Pihlstrøm L, Toft M, van Hilten JJ, Marinus J, Schulte C, Brockmann K, Sharma M, Siitonen A, Majamaa K, Eerola-Rautio J, Tienari PJ; 23andMe Research Team, Pantelyat A, Hillis AE, Dawson TM, Rosenthal LS, Albert MS, Resnick SM, Ferrucci L, Morris CM, Pletnikova O, Troncoso J, Grosset D, Lesage S, Corvol JC, Brice A, Noyce AJ, Masliah E, Wood N, Hardy J, Shulman LM, Jankovic J, Shulman JM, Heutink P, Gasser T, Cannon P, Scholz SW, Morris H, Cookson MR, Nalls MA, Gan-Or Z, Singleton AB. Blauwendraat C, et al. Brain. 2020 Jan 1;143(1):234-248. doi: 10.1093/brain/awz350. Brain. 2020. PMID: 31755958 Free PMC article.

LinkOut - more resources